Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: hop, skip and a few slips

August 22, 2018 5:23pm

Gene editing firms, CRSP and NTLA felt the sharp end of the stick while EDIT was barely positive

Another told you so …!

Pre-open indication: 5 HITs and 4 MISS (3 by pennies)

There’s a difference between trust and conviction. Trust is something you can rely on, beyond certainty. Conviction doesn't demand that you, or anyone else, play by the rules. No hard sell, get on the list for a 30 day trial!

Henry’omics:

On a macro scale, stocks tread water on Wednesday as “our” universe continued to stay up on low volume in a usual slow week even with political worries surrounding President Trump amid trade concerns.

From the pre-open newsletter: “low volume initiates another round of highs, which sooner not later will get sold into. Disruption comes in many forms - watch momentum to make sense of volatility.”

I also stated, “The sector is experiencing some new highs but, the trading piranhas are circling smelling blood from the upside!

There is going to be a sector sell-off based on trading seeking to capitalize on many of the “ups” ... but a present it is a non-event but, by Friday …?

Still trying to take some time …OFF but, not quite succeeding – rain inhibits my many yard projects (my favorite past-time).

Of the 45 companies covered on Wednesday; 12 downside equities finished in a range of -0.08% (QURE) to -5.14% (CRSP) while the 32 upside equities oscillated from +0.07% (RGNX) to +7.71% (MDXG) with 1 flat close (SGMO).

Daily analytics and metrics:

The Dow slipped 88.49 points or -0.34% to close at 25,733.80
The S&P 500 traded down -1.14 or -0.04% to close at 2,861.82
The NASDAQ rose 29.92 points or 0.38% to close at 7,889.10

Pre-open indications: 5 hits and 4 miss

Applied Genetic Technologies (AGTC) closed up +$0.05 – miss;
Audentes Therapeutics (BOLD) closed up +$0.41 – hit;
BioLife Solutions (BLFS) closed down -0.65 – hit;
CRISPR Therapeutics (CRSP) closed down -$2.65 – hit;
Editas Medicine (EDIT) closed up +$0.04 – miss;
Caladrius Bioscience (CLBS) closed down -$0.17 – hit;
Histogenics (HSGX) closed down -$0.06 – miss;
Intellia Therapeutics (NTLA) closed down -$0.34 – hit;
Verastem Oncology (VSTM) closed up +$0.24 – miss;

The advance/decline line scenario of 45 covered companies:

The open was positive with an A/DL of 30/10 and 5 flats;
The mid-day was positive with an A/DL of 30/13 and 2 flats;
The close was positive with an A/DL of 32/12 and 1 flat;

The five (5) largest trend lines:

… The greatest volume to the downside: IONS, CRSP, BLFS, AXGN and NTLA

… Upside volume was weighted to: VSTM, MDXG, PSTI, XON and ALNY

… Leadership ($) to the downside: CRSP (-$2.65), RENE.L (-$1.50), BLFS (-$0.65), IONS (-$0.57) and AXGN (-$0.50)

… Best moves ($) to the upside: BLUE (+$2.80), RARE (+$2.73), BMRN (+$1.79), GBT (+$1.60) and ONCE (+$1.54)

The iShares NASDAQ Biotechnology (IBB) closed:

Wednesday was up +0.71%
Tuesday was up +0.93%
Monday was down -0.17%
Friday was up +0.02%
Thursday was up +0.77%
Last Wednesday was down -1.56%

August sessions:

Wednesday closed POSITIVE with 12 decliners, 32 advancers and 1 flat;

Tuesday closed POSITIVE with 9 decliners, 36 advancers and 0 flat;

Monday closed POSITIVE with 16 decliners, 23 advancers and 6 flat;

Friday closed POSITIVE with 18 decliners, 24 advancers and 3 flat;

Thursday closed POSITIVE with 16 decliners, 27 advancers and 2 flat;

Wednesday closed NEGATIVE with 36 decliners, 6 advancers and 3 flat;

Tuesday closed POSITIVE with 13 decliners, 28 advancers and 4 flat;

Monday closed NEGATIVE with 24 decliners, 19 advancers and 2 flat;

Friday closed POSITIVE with 19 decliners, 24 advancers and 2 flat;

Thursday closed POSITIVE with 14 decliners, 29 advancers and 2 flat;

Wednesday closed NEGATIVE with 25 decliners, 16 advancers and 4 flat;

Tuesday closed POSITIVE with 14 decliners, 29 advancers and 2 flat;

Monday closed POSITIVE with 19 decliners, 24 advancers and 2 flat;

Friday closed NEGATIVE with 37 decliners, 4 advancers and 4 flat;

Thursday closed POSITIVE with 16 decliners, 27 advancers and 2 flat;

Last Wednesday (8/1) closed NEGATIVE with 23 decliners, 21 advancers and 1 flat;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.